2. Academic Validation
  3. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events

Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events

  • Ann Transl Med. 2019 Sep;7(17):408. doi: 10.21037/atm.2019.07.64.
Venugopal B Bhattad 1,  Sathvika Gaddam 2,  Margaret A Lassiter 3,  Pooja S Jagadish 4,  Devarshi Ardeshna 5,  Brandon Cave 6,  Rami N Khouzam 7
Affiliations

Affiliations

  • 1 Department of Internal Medicine, Division of Cardiovascular Diseases, East Tennessee State University, Johnson City, TN, USA.
  • 2 Department of Internal Medicine, East Tennessee State University, Johnson City, TN, USA.
  • 3 Cardiovascular Clinical Pharmacy Department, Johnson City Medical Center, Johnson City, TN, USA.
  • 4 Department of Internal Medicine.
  • 5 College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
  • 6 Department of Pharmacy, Methodist University Hospital, Memphis, TN, USA.
  • 7 Department of Internal Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, TN, USA.
PMID: 31660307 DOI: 10.21037/atm.2019.07.64
Abstract

Cangrelor is a relatively new antiplatelet drug that has been approved for use as an adjunct therapy to percutaneous coronary intervention (PCI) to decrease peri-procedural myocardial infarction (MI), coronary revascularization, and stent thrombosis. Cangrelor is an adenosine triphosphate analogue with a pharmacokinetic mechanism based on a reversible, dose-dependent inhibition adenosine diphosphate (ADP)-induced platelet aggregation. This drug has lately been in the spotlight as a possible bridge therapy for anti-platelet medication prior to cardiac and non-cardiac surgeries. Platelet function is usually restored within sixty minutes of cessation of therapy, thereby decreasing the risk of bleeding while providing adequate pre-procedural coverage to reduce ischemic events. This manuscript reviews the literature on cangrelor and summarizes its role as a peri-procedural bridge.

Keywords

Cangrelor; P2Y12; percutaneous coronary intervention (PCI); peri-procedural bridge.

Figures
Products